Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant releases one-year DES data

This article was originally published in The Gray Sheet

Executive Summary

Angiographic in-stent late loss and in-segment late loss with Guidant's Xience V everolimus-eluting stent are 72% and 78% lower than with Guidant's bare metal Multi-Link Vision, according to 12-month results from the firm's SPIRIT FIRST feasibility trial. Xience V showed a device-related major adverse cardiac event rate of 3.8% (1/26) compared with 21.4% (6/28) in the control arm. Xience V is also being measured against Boston Scientific's Taxus paclitaxel-eluting stent in two ongoing European trials (1"The Gray Sheet" Sept. 26, 2005, In Brief)...
Advertisement

Related Content

Guidant’s SPIRIT
Advertisement
UsernamePublicRestriction

Register

MT022917

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel